Abstract
Introduction: Historically, spontaneous bacterial peritonitis (SBP) has represented one of the most frequent and relevant infectious complications of advanced liver disease, and this is still valid today. Nevertheless, in recent years the role of fungi as causative pathogens of primary peritonitis in patients with cirrhosis has become not negligible. Another issue is linked with the traditional distinction, instrumental in therapeutic choice, between community-acquired and nosocomial forms, according to the onset. Between these two categories, another one has been introduced: the so-called “healthcare-associated infections”.
Objective: To discuss the most controversial aspects in the management of SBP nowadays in the light of best available evidence.
Methods: A review of recent literature through MEDLINE was performed.
Results: The difference between community-acquired and nosocomial infections is crucial to guide empiric antibiotic therapy, since the site of acquisition impact on the likelihood of multidrug-resistant bacteria as causative agents. Therefore, third-generation cephalosporins cannot be considered the mainstay of treatment in each episode. Furthermore, the distinction between healthcare-associated and nosocomial form seems very subtle, especially in areas wherein antimicrobial resistance is widespread, warranting broad-spectrum antibiotic regimens for both. Finally, spontaneous fungal peritonitis is a not common but actually underestimated entity, linked to high mortality. Especially in patients with septic shock and/or failure of an aggressive antibiotic regimen, the empiric addition of an antifungal agent might be considered.
Conclusion: Spontaneous bacterial peritonitis is one of the most important complications in patients with cirrhosis. A proper empiric therapy is crucial to have a positive outcome. In this respect, a careful assessment of risk factors for multidrug-resistant pathogens is crucial. Likewise important, mostly in nosocomial cases, is not to overlook the probability of a fungal ascitic infection, namely a spontaneous fungal peritonitis.
Keywords: Advanced liver diseases, cirrhosis, multidrug-resistant, spontaneous bacterial peritonitis, spontaneous fungal peritonitis, nosocomial.
Graphical Abstract
[2]
Stroffolini T, Sagnelli E, Mele A, Craxì A, Almasio P. Italian Hospitals Collaborating Group. The aetiology of chronic hepatitis in Italy: Results from a multicentre national study. Dig Liver Dis 2004; 36(12): 829-33.
[3]
Berzigotti A. Advances and challenges in cirrhosis and portal hypertension. BMC Med 2017; 15: 200.
[4]
Gentile I, Zappulo E, Buonomo AR, Maraolo AE, Borgia G. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs 2015; 24(8): 1111-21.
[5]
Morisco F, Masarone M, Rosato V, et al. Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life data from boceprevir or telaprevir based “Triple Therapy” experience in Southern Italy. Rev Recent Clin Trials 2016; 11(4): 306-16.
[6]
Enomoto M, Tamori A, Kawada N. Emerging antiviral drugs for hepatitis C virus. Rev Recent Clin Trials 2009; 4(3): 179-84.
[7]
Tosone G, Borgia G, Gentile I, et al. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided? Acta Diabetol 2007; 44(3): 167-9.
[8]
Gentile I, Viola C, Reynaud L, et al. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: Ribavirin is not always the culprit. J Interferon Cytokine Res 2005; 25(5): 283-5.
[9]
Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in the treatment of chronic Hepatitis C: The dawn of a new era. Rev Recent Clin Trials 2014; 9(1): 1-7.
[10]
Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010; 52(5): 778.
[11]
The Lancet Gastroenterology Hepatology. Treatment of hepatitis C: momentum still needed. Lancet Gastroenterol Hepatol 2018; 3(5): 289.
[12]
Gentile I, Maraolo AE, Niola M, et al. Limiting the access to direct-acting antivirals against HCV: An ethical dilemma. Expert Rev Gastroenterol Hepatol 2016; 10: 1227-34.
[13]
Orlando R, Foggia M, Maraolo AE, et al. Prevention of hepatitis B virus infection: From the past to the future. Eur J Clin Microbiol Infect Dis 2015; 34(6): 1059-70.
[14]
Schmeltzer PA, Russo MW. Clinical narrative: Autoimmune hepatitis. Am J Gastroenterol 2018; 113(7): 951-8.
[15]
Leoni S, Tovoli F, Napoli L, et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018; 24(30): 3361-73.
[16]
Almeda-Valdes P, Altamirano-Barrera A, Uribe M, Méndez-Sánchez N. Metabolic features of alcoholic liver disease. Rev Recent Clin Trials 2016; 11(3): 220-6.
[17]
Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2018; 15(12): 753-64.
[18]
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44(1): 217-31.
[19]
Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38(1): 258-66.
[20]
Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009; 43(1): 81-7.
[21]
Acevedo JG, Cramp ME. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol 2017; 9(6): 293-9.
[22]
Tripodi A, Primignani M, Mannucci PM, Caldwell SH. Changing concepts of cirrhotic coagulopathy. Am J Gastroenterol 2017; 112(2): 274-81.
[23]
Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: Evidence based treatment. World J Gastroenterol 2014; 20(18): 5442-60.
[24]
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016; 2: 16018.
[25]
Soulaidopoulos S, Cholongitas E, Giannakoulas G, Vlachou M, Goulis I. Review article: Update on current and emergent data on hepatopulmonary syndrome. World J Gastroenterol 2018; 24(12): 1285-98.
[26]
Gentile I, Buonomo AR, Scotto R, Zappulo E, Borgia G. Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. Eur J Intern Med 2017; 46: e45-7.
[27]
Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139(4): 1246-56.
[28]
Dionigi E, Garcovich M, Borzio M, et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am J Gastroenterol 2017; 12(4): 588-96.
[29]
Jalan R, Yurdaydin C, Bajaj JS, et al. World gastroenterology organization working party. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology 2014; 147(1): 4-10.
[30]
Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. J Hepatol 2014; 61: 1385-9.
[31]
Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: A position statement based on the EASL special conference 2013. J Hepatol 2014; 60(6): 1310-24.
[32]
Lutz P, Nischalke HD, Strassburg CP, Spengler U. Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol 2015; 7(3): 304-14.
[33]
Bartoletti M, Giannella M, Lewis R, et al. A prospective multicenter study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients Clin Microbiol Infect 2017; 24(5): 546 e1-546 e8.
[34]
Runyon BA. AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49(6): 2087-107.
[35]
European Association for the Study of the Liver.. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53(3): 397-417.
[36]
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69(2): 406-60.
[37]
Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: Recent guidelines and beyond. Gut 2012; 61(2): 297-310.
[38]
Karvellas CJ1. Abraldes JG, Arabi YM, Kumar A. Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-associated septic shock: A retrospective cohort study. Aliment Pharmacol Ther 2015; 41(8): 747-57.
[39]
Fiore M, Leone S. Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective. World J Gastroenterol 2016; 22(34): 7742-7.
[40]
Anastasiou J, Williams R. When to use antibiotics in the cirrhotic patient? The evidence base. Ann Gastroenterol 2013; 26(2): 128-31.
[41]
Fiore M, Maraolo AE, Leone S, et al. Spontaneous peritonitis in critically ill cirrhotic patients: a diagnostic algorithm for clinicians and future perspectives. Ther Clin Risk Manag 2017; 13: 1409-14.
[42]
Dever JB, Sheikh MY. Review article: Spontaneous bacterial peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther 2015; 41(11): 1116-31.
[43]
Fiore M, Leone S. Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective. World J Gastroenterol 2016; 22(34): 7742-7.
[44]
Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49(6): 2087-107.
[45]
Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41(3): 422-33.
[46]
Somma T, Maraolo AE, Esposito F, et al. Efficacy of ultra-short single agent regimen antibiotic chemo-prophylaxis in reducing the risk of meningitis in patients undergoing endoscopic endonasal transsphenoidal surgery. Clin Neurol Neurosurg 2015; 139: 206-9.
[48]
Van De Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: Diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect 2016; 22(Suppl. 3): 37-62.
[49]
Piccirilli G, Chiereghin A, Gabrielli L, et al. Infectious meningitis/encephalitis: Evaluation of a rapid and fully automated multiplex PCR in the microbiological diagnostic workup. New Microbiol 2018; 41(2): 118-25.
[50]
Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5(3): 457-62.
[51]
Rimola A, Salmerón JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology 1995; 21(3): 674-9.
[52]
Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111(4): 1011-7.
[53]
Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341(6): 403-9.
[54]
Ricart E, Soriano G, Novella MT, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 2000; 32(4): 596-602.
[55]
Soares-Weiser K, Brezis M, Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotics. Cochrane Database Syst Rev 2001; 3CD002232
[56]
Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18(3): 268-81.
[57]
Botwin GJ, Morgan TR. Bacterial infections in cirrhosis. Hepatol Int 2014; 8(Suppl. 2): 467-74.
[58]
Piano S, Brocca A, Mareso S, Angeli P. Infections complicating cirrhosis. Liver Int 2018; 38(Suppl. 1): 126-33.
[59]
Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. Hepatology 2012; 55(5): 1551-61.
[60]
Tandon P, DeLisle A, Topal JE, Garcia-Tsao G. High prevalence of antibiotic- resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol 2012; 10(11): 1291-8.
[61]
Maraolo AE, Gentile I, Pinchera B, Nappa S, Borgia G. Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. Expert Opin Pharmacother 2018; 19(12): 1317-25.
[62]
Fernández J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56(Suppl. 1): S1-S12.
[63]
Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol 2016; 8(6): 307-21.
[64]
Fiore M, Maraolo AE, Gentile I, et al. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis. World J Hepatol 2017; 9(30): 1166-75.
[65]
Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 2011; 17(10): 1581-6.
[66]
Fiore M, Maraolo AE, Gentile I, et al. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review. World J Gastroenterol 2017; 23(25): 4654-60.
[67]
Fiore M, Gentile I, Maraolo AE, et al. Are third-generation cephalosporins still the empirical antibiotic treatment of community acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30(3): 329-36.
[68]
Weist K, Högberg LD. ECDC publishes 2015 surveillance data on antimicrobial resistance and antimicrobial consumption in Europe. Euro Surveill 2016; 21(46): pii 30399.
[69]
Morehead MS, Scarbrough C. Emergence of Global Antibiotic Resistance. Prim Care 2018; 45(3): 467-84.
[70]
Ison MG. Empiric treatment of nosocomial spontaneous bacterial peritonitis: one size does not fit all. Hepatology 2016; 63(4): 1083-5.
[71]
Viceconte G, Maraolo AE, Iula VD, Catania MR, Tosone G, Orlando R. Appropriateness of antibiotic prescription for targeted therapy of infections caused by multidrug-resistant bacteria: assessment of the most common improper uses in a tertiary hospital in southern Italy. Infez Med 2017; 25(3): 224-33.
[72]
Menichetti F, Falcone M, Lopalco P, et al. The GISA call to action for the appropriate use of antimicrobials and the control of antimicrobial resistance in Italy. Int J Antimicrob Agents 2018; 52(2): 127-34.
[73]
Piano S, Fasolato S, Salinas F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology 2016; 63(4): 1299-309.
[74]
Maraolo AE, Giacobbe DR, Fiore M. The diagnostic conundrum of bacterial infections in cirrhotic patients. Liver Int 2017; 37(9): 1411.
[75]
Nadim MK, Durand F, Kellum JA, et al. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol 2016; 64(3): 717-35.
[76]
Arabi YM, Dara SI, Memish Z, et al. Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. Hepatology 2012; 56(6): 2305-15.
[77]
Carey W, Boayke A, Leatherman J. Spontaneous bacterial peritonitis, clinical and laboratory features with reference to hospital acquired cases. Am J Gastroenterol 1986; 81(12): 1156-61.
[78]
Cardoso T, Almeida M, Friedman ND, et al. Classification of healthcare-associated infection: A systematic review 10 years after the first proposal. BMC Med 2014; 12: 40.
[79]
Carratalà J, Garcia-Vidal C. What is healthcare-associated pneumonia and how is it managed? Curr Opin Infect Dis 2008; 21(2): 168-73.
[80]
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63(5): e61-e111.
[81]
Metersky ML, Kalil AC. New guidelines for nosocomial pneumonia. Curr Opin Pulm Med 2017; 23(3): 211-7.
[82]
Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: A need for care coordination. Clin Gastroenterol Hepatol 2013; 11(3): 217-23.
[83]
Merli M, Lucidi C, Di Gregorio V, et al. The spread of multi-drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: A prospective survey. PLoS One 2015; 10(5)e0127448
[84]
Lutz P, Nischalke HD, Krämer B, et al. Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis. Eur J Clin Invest 2017; 47(1): 44-52.
[85]
Merli M, Lucidi C, Di Gregorio V, et al. An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial. Hepatology 2016; 63(5): 1632-9.
[86]
Fiore M, Chiodini P, Pota V, et al. Risk of spontaneous fungal peritonitis in hospitalized cirrhotic patients with ascites: A systematic review of observational studies and meta-analysis. Minerva Anestesiol 2017; 83(12): 1309-16.
[87]
Bajaj JS, Rajender Reddy K, Tandon P, et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am J Gastroenterol 2018; 113(4): 556-63.
[88]
Alexopoulou A, Vasilieva L, Agiasotelli D, Dourakis SP. Fungal infections in patients with cirrhosis. J Hepatol 2015; 63(4): 1043-5.
[89]
Bucsics T, Schwabl P, Mandorfer M, Peck-Radosavljevic M. Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). J Hepatol 2016; 64(6): 1452-4.
[90]
Yang C, Yeh CT, Hung CF, Liaw YF. Case report: spontaneous peritonitis caused by Candida albicans. J Gastroenterol Hepatol 1999; 14(10): 1041-4.
[91]
Nair S, Kumar KS, Sachan P, Corpuz M. Spontaneous fungal peritonitis (Candida glabrata) in a patient with cirrhosis. J Clin Gastroenterol 2001; 32(4): 362-4.
[92]
Shizuma T. Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review. World J Hepatol 2018; 10(2): 254-66.
[93]
Hwang SY, Yu SJ, Lee JH, et al. Spontaneous fungal peritonitis: A severe complication in patients with advanced liver cirrhosis. Eur J Clin Microbiol Infect Dis 2014; 33(2): 259-64.
[94]
Bremmer DN, Garavaglia JM, Shields RK. Spontaneous fungal peritonitis: A devastating complication of cirrhosis. Mycoses 2015; 58(7): 387-93.
[95]
Lahmer T, Brandl A, Rasch S, Schmid RM, Huber W. Fungal peritonitis: Underestimated disease in critically ill patients with liver cirrhosis and spontaneous peritonitis. PLoS One 2016; 11(7)e0158389
[96]
Gravito-Soares M, Gravito-Soares E, Lopes S, Ribeiro G, Figueiredo P. Spontaneous fungal peritonitis: A rare but severe complication of liver cirrhosis. Eur J Gastroenterol Hepatol 2017; 29(9): 1010-6.
[97]
Piano S, Angeli P. Reply to Preemptive therapy of spontaneous fungal peritonitis. Hepatology 2016; 64(3): 998-9.
[98]
Bassetti M, Peghin M, Carnelutti A, et al. Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: A multicenter study. Intensive Care Med 2017; 43(4): 509-18.
[99]
Manning ML, Septimus EJ, Ashley ESD, et al. Antimicrobial stewardship and infection prevention-leveraging the synergy: a position paper update. Infect Control Hosp Epidemiol 2018; 39(4): 467-72.
[100]
Gentile I, Maraolo AE, Borgia G. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Expert Rev Anti Infect Ther 2016; 14(10): 875-8.
[101]
Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: A randomized clinical trial. JAMA Surg 2017; 152(3): 224-32.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Biotechnology and Drug Development for Targeting Human Diseases
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Enzymatic Targets for Drug Discovery Against Alzheimer's Disease
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
Brain Tumor Targeting Drug Delivery Systems: Advanced Nanoscience for Theranostics Applications
Article Metrics
62
2